Sands Capital Ventures’s Tarsus Pharmaceuticals TARS Stock Holding History

Sands Capital Ventures’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.68M	Hold	85,000	–	–	0.96%	18
2026 Q2	$5.35M	Hold	85,000	–	–	0.87%	20
2026 Q1	$5.96M	Hold	85,000	–	–	1.42%	14
2025 Q4	$6.96M	Sell	85,000 -85,000	-50%	-$6.35M	1.34%	15
2025 Q3	$10.1M	Hold	170,000	–	–	2.21%	10
2025 Q2	$6.89M	Hold	170,000	–	–	1.36%	12
2025 Q1	$8.73M	Hold	170,000	–	–	2.14%	10
2024 Q4	$9.41M	Hold	170,000	–	–	2.05%	10
2024 Q3	$5.59M	Hold	170,000	–	–	1.57%	10
2024 Q2	$4.62M	Hold	170,000	–	–	1.55%	9
2024 Q1	$6.18M	Sell	170,000 -90,000	-35%	-$2.65M	1.49%	9
2023 Q4	$5.26M	Hold	260,000	–	–	1.46%	10
2023 Q3	$4.62M	Hold	260,000	–	–	1.37%	12
2023 Q2	$4.7M	Hold	260,000	–	–	1.39%	10
2023 Q1	$3.27M	Hold	260,000	–	–	0.81%	12
2022 Q4	$3.81M	Hold	260,000	–	–	1.04%	13
2022 Q3	$4.45M	Hold	260,000	–	–	1.29%	12
2022 Q2	$3.8M	Hold	260,000	–	–	1.04%	13
2022 Q1	$4.37M	Hold	260,000	–	–	0.91%	14
2021 Q4	$5.85M	Hold	260,000	–	–	0.87%	14
2021 Q3	$5.6M	Buy	+260,000	New	+$6.44M	0.84%	11

Other funds holding TARS

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Sands Capital Ventures's TARS Position: Q3 2026 in Review

Sands Capital Ventures held its Tarsus Pharmaceuticals (TARS) position steady in Q3 2026 at 85,000 shares worth $6.68M. The position accounts for 0.96% of the portfolio, ranked #18.

Sands Capital Ventures first reported a position in TARS in Q3 2021 and has held it in 21 quarters since. The position peaked at $10.1M in Q3 2025. 176 funds tracked by Wall St. Rank hold TARS as of Q3 2026.

Sands Capital Ventures held 85,000 shares of Tarsus Pharmaceuticals worth $6.68M as of Q3 2026.
Sands Capital Ventures left its Tarsus Pharmaceuticals share count unchanged in Q3 2026.
Tarsus Pharmaceuticals made up 0.96% of Sands Capital Ventures's portfolio in Q3 2026, its #18 holding.
Sands Capital Ventures first reported a position in Tarsus Pharmaceuticals in Q3 2021 and has held it in 21 quarters since.
Sands Capital Ventures's Tarsus Pharmaceuticals position peaked at $10.1M in Q3 2025.
176 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.

Based on Sands Capital Ventures's 13F filing for Q3 2026, filed 13 Nov 2026.